SCHEMBL988070

SCHEMBL988070

CCOC(=O)c1cccc2c1NCCC2

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.50
SRC P12931 1/20 0.47
HSD17B10 Q99714 3/20 0.46
ALDH1A1 P00352 4/20 0.44
MAPT P10636 4/20 0.42
KMT2A Q03164 3/20 0.42
CYP1A2 P05177 3/20 0.42
CYP2C9 P11712 2/20 0.42
CYP2C19 P33261 2/20 0.42
MEN1 O00255 2/20 0.42
USP2 O75604 2/20 0.42
CLEC4M Q9H2X3 1/20 0.42
CYP3A4 P08684 1/20 0.42
ALOX15 P16050 1/20 0.42
MAPK10 P53779 1/20 0.42
PTK2B Q14289 1/20 0.42
NCOA1 Q15788 1/20 0.42
NCOA3 Q9Y6Q9 1/20 0.42
KDM4E B2RXH2 3/20 0.42
ADRA1D P25100 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3630293 0.84 SRC (0.50) TSHRSRCHSD17B10ALDH1A1MAPT
SCHEMBL3729724 0.79 SRC (0.50) SRCALDH1A1MAPTKDM4ERAB9A
SCHEMBL5801932 0.78 SRC (0.45) SRCHSD17B10ALDH1A1KMT2AALOX15
SCHEMBL3500161 0.78 TSHR (0.50) TSHRHSD17B10ALDH1A1MAPTKMT2A
SCHEMBL6983702 0.78 SRC (0.47) TSHRSRCADRA1DADRA1AADRA1B
SCHEMBL30647012 0.77 SRC (0.51) SRCHSD17B10ALDH1A1MAPTKMT2A
SCHEMBL1520555 0.77 SRC (0.51) SRCHSD17B10ALDH1A1MAPTKMT2A
SCHEMBL3308704 0.77 CXCR5 (0.47)
SCHEMBL7940212 0.77 TSHR (0.49) TSHRHSD17B10ALDH1A1MAPTKMT2A
SCHEMBL7276418 0.77 TSHR (0.56) TSHRHSD17B10ALDH1A1MAPTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8598355-B2 Amide compound ASTELLAS PHARMA INC. (JP) 2013-12-03 US disclosed
EP-2565191-A1 4-(Indol-7-ylcarbonylaminomethyl)cyclohexanecarboxylic acid derivatives as EP4 receptor antagonists useful for the treatment of chronic renal failure or diabetic nephropathy Astellas Pharma Inc. (JP) 2013-03-06 EP disclosed
US-20110144153-A1 AMIDE COMPOUND ASTELLAS PHARMA INC. (JP) 2011-06-16 US disclosed
EP-2277858-A1 AMIDE COMPOUND Astellas Pharma Inc. (JP) 2011-01-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110144153-A1 AMIDE COMPOUND PTGER4, PTGER1, PTGER2 TSHR 1014/4885SRC 3727/4885HSD17B10 3004/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.